These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9892169)

  • 1. Candesartan and progression of preglomerular lesions in N(G)-nitro-L-arginine methyl ester hypertensive rats.
    Casellas D; Benahmed S; Artuso A; Jover B
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S230-3. PubMed ID: 9892169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide and preglomerular vascular lesions in lyon spontaneously hypertensive rats.
    Casellas D; Bouriquet N; Artuso A
    Acta Physiol Scand; 2000 Jan; 168(1):133-8. PubMed ID: 10691791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New method for imaging innervation of the renal preglomerular vasculature. Alterations in hypertensive rats.
    Casellas D; Bouriquet N; Artuso A; Walcott B; Moore LC
    Microcirculation; 2000 Dec; 7(6 Pt 1):429-37. PubMed ID: 11142340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitric oxide participates in the renal vasodilatory effect of candesartan in anesthetized rats.
    Demeilliers B; Mimran A; Jover B
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S208-12. PubMed ID: 9892165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition.
    Okazaki H; Minamino T; Tsukamoto O; Kim J; Okada K; Myoishi M; Wakeno M; Takashima S; Mochizuki N; Kitakaze M
    Hypertens Res; 2006 Apr; 29(4):277-84. PubMed ID: 16778335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of hypertension and renal injury by salt-loading during chronic nitric oxide inhibition. Effects of TCV-116, a novel angiotensin II receptor antagonist.
    Okamura M; Konishi Y; Nishimura M; Umetani N; Iwai J; Negoro N; Inoue T; Takeda T; Kanayama Y
    Blood Press Suppl; 1994; 5():75-8. PubMed ID: 7889207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination against the angiotensin type 1 receptor for the prevention of L-NAME-induced nephropathy.
    Azegami T; Sasamura H; Hayashi K; Itoh H
    Hypertens Res; 2012 May; 35(5):492-9. PubMed ID: 22158111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined treatment with ibuprofen and the AT1 receptor antagonist candesartan in young spontaneously hypertensive rats.
    Pollock DM; Morsing P
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S116-9. PubMed ID: 9892151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal responses of the nonclipped kidney of two-kidney/one-clip Goldblatt hypertensive rats to type 1 angiotensin II receptor blockade with candesartan.
    Cervenka L; Navar LG
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S197-201. PubMed ID: 9892163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candesartan prevents L-NAME-induced cardio-renal injury in spontaneously hypertensive rats beyond hypotensive effects.
    Casellas D; Herizi A; Artuso A; Mimran A; Jover B
    J Renin Angiotensin Aldosterone Syst; 2001 Mar; 2(1_suppl):S84-S90. PubMed ID: 28095223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candesartan cilexetil protects against loss of autoregulatory efficiency in angiotensin II-infused rats.
    Inscho EW; Imig JD; Deichmann PC; Cook AK
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S178-83. PubMed ID: 9892160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developmental activity of the renin-angiotensin system during the "critical period" modulates later L-NAME-induced hypertension and renal injury.
    Ishiguro K; Sasamura H; Sakamaki Y; Itoh H; Saruta T
    Hypertens Res; 2007 Jan; 30(1):63-75. PubMed ID: 17460373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preglomerular sudanophilia in L-NAME hypertensive rats: involvement of endothelin.
    Bouriquet N; Dupont M; Herizi A; Mimran A; Casellas D
    Hypertension; 1996 Mar; 27(3 Pt 1):382-91. PubMed ID: 8698442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of the inhibitory effect of N(G)-nitro-L-arginine methyl ester on the antihypertensive effect of the angiotensin AT1 receptor antagonist, GR138950.
    Anderson IK; Drew GM
    Br J Pharmacol; 1997 Dec; 122(7):1385-94. PubMed ID: 9421286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Contribution of the renin-angiotensin system to the variability of blood pressure in hypertensive rat after blockade of nitric oxide synthesis].
    Gouédard O; Gaudet E; Blanc J; Ponchon P; Elghozi JL
    Arch Mal Coeur Vaiss; 1996 Aug; 89(8):1013-7. PubMed ID: 8949370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin-angiotensin blockade improves renal cGMP production via non-AT(2)-receptor mediated mechanisms in hypertension-induced by chronic NOS inhibition in rat.
    Uhlenius N; Vuolteenaho O; Tikkanen I
    J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):233-9. PubMed ID: 11881129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bosentan prevents preglomerular alterations during angiotensin II hypertension.
    Casellas D; Bouriquet N; Herizi A
    Hypertension; 1997 Dec; 30(6):1613-20. PubMed ID: 9403591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preserving target-organ function with candesartan cilexetil in patients with hypertension.
    Zannad F
    Blood Press Suppl; 2000; 1():36-9. PubMed ID: 11059635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rofecoxib on antihypertensive effects of candesartan in experimental models of hypertension.
    Jain S; Gupta M; Malhotra S; Pandhi P
    Methods Find Exp Clin Pharmacol; 2005; 27(1):11-6. PubMed ID: 15834454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.